Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 plus cetrelimab versus cetrelimab alone before radical cystectomy in muscle-invasive bladder cancer
MOH_2022-10-18_011875Phase 2Active, not recruiting
- Sponsor
- Janssen-Cilag
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC) comparing TAR-200 + cetrelimab with cetrelimab (2 arms). Started May 2022; status: active, not recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on MOH_2022-10-18_011875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-18_011875.